期刊文献+

甲状腺微小乳头状癌颈部中央区淋巴结转移的临床特点分析 被引量:2

Clinical characteristics of intermediate-cervical lymph node metastasis of papillary thyroid microcarcinoma
下载PDF
导出
摘要 目的分析甲状腺微小乳头状癌(PTMC)颈部中央区淋巴结转移的临床特点及影响因素。方法回顾性分析249例PTMC患者的临床资料,探讨PTMC患者颈部中央区淋巴结转移的临床特点及影响因素。结果 PTMC患者颈部中央区淋巴结转移率为39.8%(99/249)。单因素、多因素分析结果均显示,年龄<45岁、肿瘤多灶、肿瘤直径>5 mm、肿瘤穿透被膜是影响颈部中央区淋巴结转移的危险因素。结论 PTMC患者颈部中央区淋巴结转移率较高,对于年龄<45岁、肿瘤多灶、肿瘤直径>5 mm、肿瘤穿透被膜的患者更应警惕中央区淋巴结转移的可能。 Objective To analyze the clinical characteristics and influencing factors of intermediate-cervical lymph node metastasis of papillary thyroid microcarcinoma(PTMC). Methods Clinical data of 249 patients with PTMC were analyzed retrospectively to investigate the clinical characteristics and influencing factors of intermediate-cervical lymph node metastasis in patients with PTMC. Results The rate of intermediate-cervical lymph node metastasis was 39.8% (99/249) in patients with PTMC. The results of univariate and multivariate analysis showed that age 〈45 years,multffocal tumor,tumor diameter 〉 5 mm,and extranodal extension were the risk factors influencing intermediate-cervical lymph node metastasis. Conclusion The rate of iiatermediate-ccrvical lymph node metastasis is quite high among patients with PTMC. We should be alert to patients with age 〈45 years,multifocal tumor,tumor diameter 〉5 mm,and extranodal extension for the possibility of intermediate-cervical lymph node metastasis.
作者 庞飞雄 张嘉越 冷津立 李松明 PANG Fei-xiong ZHANG Jia-yue LENG Jin-li LI Song-ruing(Department of General Surgery,NO. 303 Hospital of Chinese People's Liberation Army,Nanning 530021, China)
出处 《广西医学》 CAS 2017年第10期1505-1507,共3页 Guangxi Medical Journal
关键词 甲状腺微小乳头状癌 中央区淋巴结转移 危险因素 临床特点 Papillary thyroid microcarcinoma, Intermediate-cervical lymph node metastasis, Risk factor, Clinical characteristics
  • 相关文献

参考文献7

二级参考文献94

  • 1陈勇,陈建国,沈洪兵,徐耀初.启东1972~2001年恶性肿瘤发病率时间趋势分析[J].疾病控制杂志,2006,10(2):105-108. 被引量:16
  • 2Nagasaki S,Nystrom E. Epidemiology and primary prevention ofthyroid cancer. Thyroid,2002,12(10) :889-896.
  • 3Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2000. Cancerincidence, mortality and prevalence worldwide. IARC Press,Lyon,2001.
  • 4National Cancer Institute (NCI). Surveillance, Epidemiology, andEnd Results (SEER) Incidence and U.S. Mortality Statistics,2002.
  • 5全国肿瘤防治研究办公室.2010年中国肿瘤登记年报.北京:军事医学科学出版社,2011.
  • 6Ferlay J, Shin HR, Bary F, et al. Estimates of worldwide burdenof cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010, 127(12):2893-2917.
  • 7Statistical Research Applications Branch in National CancerInstitute, U.S.A. Joinpoint software [EB/OL]. http://srab.cancer.gov/Joinpoint. 2007-10-20.
  • 8Ferlay J,Shin HR,Bary F,et al. GLOBOCAN 2008 vl.2,CancerIncidence and Mortality Worldwide : IACR Cancer Base No. 10[internet]. Lyon, France: International Agency for Research onCaner,2010. Available from: http://globocan.iacr.fr,accessed on30/10/2011.
  • 9Lope V, Perez GB, Aragones N,et al. Occupational exposure toionizing radiation and electromagnetic fields in relation to therisk of thyroid cancer in Sweden. Scand J Work Environ Health,2006,32:276-284.
  • 10Baker SR, Bhatti WA. The thyroid cancer epidemic:is it the darkside of the CT revolution. Eur J Radiol,2006,60 : 67- 69.

共引文献596

同被引文献15

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部